Keyword: Antibodies

ABSTRACT: Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies, highlighting the need for sensitive and selective cancer cell detection. Optical fiber biosensors offer high sensitivity, compact size, and label-free operation for cancer cell detection. This study developed a quasi-random extrinsic interferometer-based fiber-optic biosensor for label-free TNBC cell detection using two complementary recognition strategies: gold–anti-CD44 antibody functionalization and polydopamine (PDA)-based molecularly imprinted polymer (MIP) recognition. The performance of these functionalized sensors was evaluated for selective recognition of TNBC cells, demonstrating their potential as a sensitive and label-free detection platform.
Materials and Methods: A quasi-random extrinsic interferometer-based fiber-optic sensor was fabricated and coated with polydimethylsiloxane (PDMS), a biocompatible polymer widely used in biomedical applications. For antibody-based recognition, a gold-coated surface was functionalized with anti-CD44 antibodies to target HCC1806 breast cancer cells, with HEK293 cells used as a control. For synthetic recognition, dopamine was polymerized on the sensor surface to form a polydopamine (PDA)-based molecularly imprinted polymer (MIP) designed to recognize HCC1806 and MDA-MB-231 cells. Optical responses at different cell concentrations were recorded using a fiber-optic interrogator, and sensor performance and cell attachment were evaluated by calibration analysis and scanning electron microscopy.
Results and Conclusions: The developed fiber-optic biosensors show potential for integration into liquid biopsy platforms for label-free detection of circulating tumor cells in biological fluids, providing a rapid and minimally invasive approach for cancer detection and monitoring.

ABSTRACT: Introduction: Fiber-optic biosensors generate complex, multichannel interferometric data affected by baseline noise and drift, which must be filtered and converted into standardized performance metrics before they can support cancer cell detection claims. Our group's fiber-optic biosensing programme uses two recognition strategies — a surface plasmon resonance anti-CD44 immunosensor and a PDA-based molecularly imprinted polymer sensor — for TNBC cell lines detection, yet both rely on the same challenge: extracting reliable calibration data from noisy, multi-channel wavelength-shift signals. To address this gap, a computational signal-processing framework was developed and validated that applies baseline correction and noise filtering, automatically identifies high-sensitivity spectral channels, fits calibration curves, and computes limit of detection, coefficient of determination, repeatability, and selectivity, and was applied to quantify and compare the two TNBC biosensor platforms.
Materials and Methods: A computational/analytical approach was applied to previously acquired experimental data. Raw transmission spectra from 8-channel quasi-random extrinsic interferometric fiber-optic sensors were used: (1) the SPR-based anti-CD44 immunosensor exposed to HCC1806 TNBC cells and HEK293 control cells, and (2) the PDA-based MIP sensor exposed to HCC1806 and MDA-MB-231 TNBC cells. Raw spectra were first denoised using a 5th-order Butterworth filter combined with baseline subtraction to correct for high-frequency noise and baseline drift prior to peak identification. For each channel, a custom peak/valley-detection algorithm implemented in MATLAB identified interference fringes and tracked wavelength position across cell concentrations. The sub-range with the steepest slope was selected as the optimal operating range per sensor. Calibration curves were fitted by linear regression, with the coefficient of determination (R²) as fit quality. Limit of detection (LoD) was calculated as 3σ of the blank response divided by calibration slope. Repeatability was assessed as coefficient of variation across replicates; selectivity by comparing target-cell versus non-target/control responses.
Results and Conclusions: The developed computational framework successfully processed multichannel interferometric data from both the SPR-based immunosensor and the MIP-based biosensor, automatically identifying high-sensitivity spectral channels and extracting calibration-based performance metrics — including limit of detection, coefficient of determination, repeatability, and selectivity — for each. Filtering with the Butterworth and baseline-subtraction steps improved spectral clarity by suppressing high-frequency noise and drift, yielding calibration curves with higher sensitivity and improved linearity. This provided a consistent, standardized basis for comparing the two recognition strategies and demonstrates the framework's potential as a common analytical backbone for future fiber-optic biosensor platforms in oncology, extendable to currently unanalyzed sensor datasets.

ABSTRACT: Introduction: POEMS syndrome is a rare paraneoplastic disorder associated with plasma cell dyscrasia and characterized by a combination of organomegaly, peripheral polyneuropathy, endocrinopathies, osteosclerotic lesions, monoclonal shedding, and typical skin changes. Diagnosis is challenging due to the nonspecific clinical presentation and minimal bone marrow infiltration. Currently, treatment approaches remain nonstandard, and the use of anti-CD38 therapy is limited.
Objective: To demonstrate the complexity and duration of diagnosis of POEMS syndrome and evaluate the clinical effect of anti-CD38 therapy.
Materials And Methods: A retrospective analysis of clinical, laboratory, and imaging data from a 38-year-old patient seen at the National Cancer Research Center was conducted. Diagnostic evaluation included serum enzyme-linked immunosorbent assay, vascular endothelial growth factor (VEGF) levels, PET/CT, bone marrow examination, and assessment of compliance with the Dispenzieri 2019 criteria. Treatment efficacy was assessed based on clinical symptoms and laboratory findings.
Results: The patient was diagnosed with polyneuropathy, organomegaly, extravascular fluid overload, endocrinopathy, monoclonal IgG-λ secretion, and significantly elevated VEGF levels. Minimal plasma cell infiltration was noted in the bone marrow. POEMS syndrome was diagnosed. Treatment with Daratumumab-Lenalidomide-Dexamethasone (Dara-RD) resulted in significant clinical improvement, decreased edema, and stabilization of laboratory parameters.
Conclusion: This case demonstrates the complexity of diagnosing POEMS syndrome with minimal bone marrow infiltration, severe systemic manifestations, and problems with long-term diagnostic verification, lasting for 5 years (from 2019 to 2025). Daratumumab-Lenalidomide-Dexamethasone (DaraRD) therapy has demonstrated significant clinical benefit and can be considered a progressive treatment option for severe forms of the disease.